

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

12 C<sub>1-8</sub>alkyl-C<sub>3-8</sub>cycloalkyl, -O-R<sup>2</sup>, -O-C(=O)R<sup>2</sup>, -C<sub>1-8</sub>alkyl-O-R<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)R<sup>10</sup>,  
13 -C<sub>1-8</sub>alkyl-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>,  
14 -C<sub>1-8</sub>alkyl-NR<sup>10</sup>R<sup>10</sup>, -C<sub>1-8</sub>alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where R<sup>2</sup> is as described above and  
15 R<sup>10</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl,  
16 C<sub>2-8</sub>alkynyl, and wherein when two R<sup>10</sup> groups are present they may be taken together to  
17 form a saturated or unsaturated ring with the atom to which they are both attached;  
18 each R<sup>14</sup> group is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-</sub>  
19 <sub>8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH,  
20 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, C<sub>1-8</sub>alkyl-OH, C<sub>0-8</sub>alkyl-SH, -O-R<sup>2</sup> and  
21 -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or di-substituted amino group,  
22 wherein the substituted amino groups are independently substituted by at least one  
23 member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl,  
24 C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH and C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl;  
25 or a pharmaceutically acceptable diastereomer, salt, hydrate, and solvate thereof.

#### REMARKS

Claims 1-16 are pending in this application and presented for examination. Claims 1-2, 5, 9 and 11 have been amended. No new matter has been introduced with the foregoing amendments. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made." Reconsideration is respectfully requested.

#### **I. REJECTION UNDER 35 U.S.C. § 112, second paragraph**

Claims 1-16 were rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite. To the extent the rejection is applicable to the amended set of claims, Applicants respectfully traverse the rejection.

Each of the Examiner's concerns, and Applicants response to those concerns, will be addressed in turn.

a) With respect to the double inclusion of the variable "OH" in R<sup>1</sup> and R<sup>14</sup>, Applicants have amended "C<sub>0</sub>-C<sub>6</sub>alkyl-OH" to set forth C<sub>1</sub>-C<sub>6</sub>alkyl-OH. As such, Applicants respectfully request that the Examiner withdraw the rejection.

b) With respect to the typographical errors of r<sup>6</sup> and r<sup>18</sup>, Applicants have amended the claims to set forth R<sup>6</sup> and R<sup>18</sup>. As such, Applicants respectfully request that the Examiner withdraw the rejection.

c) With respect to the term "prodrug derivatives", Applicants have deleted the term from the claims in an earnest effort to advance prosecution of the application. As such, Applicants respectfully request that the Examiner withdraw the rejection.

d) With respect to the term "containing" in the definition of "heterocycle", Applicants have followed the Examiner's suggestion and amended the claims to set forth "having". As such, Applicants respectfully request that the Examiner withdraw the rejection.

In view of the foregoing amendments, Applicants respectfully request that the Examiner withdraw the rejections under 35 U.S.C. § 112, second paragraph.

## **II. REJECTION UNDER 35 U.S.C. § 112, first paragraph**

Claims 1-16 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly being non-enabled for the term "prodrug derivative".

In an earnest effort to advance prosecution of the application, Applicants have amended the claims to delete the term. As such, Applicants respectfully request that the Examiner withdraw the rejection.

Claims 14-15 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly being non-enabled for preventing a condition...characterized by undesired thrombosis. In response, Applicants respectfully traverse the rejection.

Applicants respectfully point out that the proper standard for determining whether the claims are adequately enabled is whether undue experimentation is required by one skilled in the art to practice the invention. The analysis includes consideration of

factors such as the amount of guidance provided in the application and the presence of working examples. *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Int. 1985); *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988).

In the instant case, the claims are adequately enabled for treating the various conditions and indication set forth in claims 14-15, as one of ordinary skill in the art can practice the claimed invention without undue experimentation. As set out in *Wands*, “a *considerable* amount of experimentation is permissible, if it is merely *routine*, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should precede.” *In re Wands*, 8 USPQ2d at 1404 (quoting *In re Jackson*, 217 USPQ 804 (Bd. Pat. App. & Int. 1982) (Emphasis added)).

Clearly, in the instant application, the amount of experimentation is not undue as the specification gives adequate guidance. In this respect, the Examiner’s attention is respectfully directed to page 32, lines 13-17 of the present specification, wherein it teaches:

The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the *in vitro* protease activity assays and *in vivo* studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.

Specific assays both *in vivo* and *in vitro*, to teach the biological efficacy are set forth in detail on page 41, line 24, continuing to the top of page 43. For example, amidolytic assays for determining protease inhibition activity has been described. These assays include, factor Xa and thrombin assays as well as prothrombinase inhibition assays.

In addition, the antithrombotic efficacy of the compounds was assayed in a rabbit model of venous thrombosis, using a rabbit deep vein thrombosis model as described by Hollenbach, S. *et al.*, *Thromb. Haemost.* 71, 357-362 (1994), wherein the *in-vivo* antithrombotic activity of the test compounds was determined.

Further, guidance is given in the biological data table set forth on page 46. As tabulated therein, 19 compounds were tested with a battery of biological assay. Based on the evidence regarding the detailed guidance set forth above, the specification at the time the application was filed, would have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

Moreover, Applicants assert that the number of working examples disclosed in the specification is sufficient to enable the full scope of the claims. Applicants are not required to disclose every type of indications within "undesired thrombosis". For example, in *In re Angstadt*, the court decided that Applicants "are not required to disclose every species encompassed by their claims even in an unpredictable art" and that "the disclosure of forty working examples sufficiently described the subject matter of claims directed to a generic process." 537 F.2d at 502-03, 190 USPQ at 218. As such, if Applicants show efficacy for the treatment of undesired thrombosis, such as with a factor Xa assay, a thrombin assay as well as prothrombinase inhibition assay, they are entitled to sub-indications within such indication.

Accordingly, Applicants respectfully request that this rejection be withdrawn.

### **III. REJECTION UNDER 35 U.S.C. 102(a)**


Claims 1-2 and 13-16 were rejected under 35 U.S.C. § 102(a) as allegedly being anticipated by WO 99/50254 ("Dudley *et al.*"). To the extent the rejection is applicable to the amended set of claims, Applicants respectfully traverse the rejection.

"To anticipate a claim, a reference must disclose every element of the challenged claim and enable one skilled in the art to make the anticipating subject matter" (*see, PPG Industries Inc. v. Guardian Industries Corp.*, 37 USPQ2d 1618, 1624 (Fed. Cir. 1996)).

Applicants have amended the structure in claim 1 to set forth quinolone derivatives. Applicants note that in no instance does Dudley *et al.* teach or suggest

quinolone derivatives *i.e.*, when "X" of the present Formula I is CR<sup>12</sup>. As such, these derivatives are neither anticipated nor rendered obvious in view of Dudley *et al.*

Applicants have amended claim 2 to set forth quinoxalone derivatives, wherein "A" in Formula I, is a member selected from the following:



and Z is a member selected from the group of C<sub>1-8</sub>alkyl, C<sub>3-8</sub>cycloalkyl, and a five to ten membered heterocyclic ring system having 1-4 heteroatoms selected from the group consisting of N, O and S;

D is a member selected from the group of a direct link, -CH<sub>2</sub>-, -O-, -N(R<sup>2</sup>)-, -C(=O)-, -S-, -SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>2</sup>)-, -N(R<sup>2</sup>)-SO<sub>2</sub>-, -OC(=O)-, -C(=O)O-, -C(=O)-N(R<sup>2</sup>)- and -N(R<sup>2</sup>)-C(=O)-, provided that when Z is C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>carbocyclic aryl, then D is -O-, or -N(R<sup>2</sup>)-. The other variables have not been changed. This embodiment is not taught, suggested or disclosed in Dudley *et al.* As such, the instant invention is neither anticipated or rendered obvious in view of the cited art.

As such, Applicants respectfully request that the Examiner withdraw the rejection.

#### IV. CONCLUSION


In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Bing-Yang Zhu *et al.*  
Application No.: 09/773,374  
Page 21

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925.472.5000.

Respectfully submitted,



Joseph R. Snyder  
Reg. No. 39,381



TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: (415) 576-0300  
JS:js  
WC 9047272 v1

DONOT  
 ENTER

PATENT



VERSION WITH MARKINGS TO SHOW CHANGES MADE in *Amendment A*

1. (Amended) A compound of having the following formula:



wherein:

A is a member selected from the group consisting of:  $\text{R}^2$ ,  $-\text{NR}^3\text{R}^4$ ,  $-\text{C}(=\text{O})\text{NR}^3\text{R}^4$ ,



where  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ , and  $\text{R}^9$  are independently selected from the group consisting of H, -OH,  $\text{C}_{1-8}$ alkyl,  $\text{C}_{2-8}$ alkenyl,  $\text{C}_{2-8}$ alkynyl,  $\text{C}_{3-8}$ cycloalkyl,  $\text{C}_{6-12}$ carbocyclic aryl, a five to ten membered heterocyclic ring system [containing] having 1-4



10 heteroatoms selected from the group consisting of N, O and S; and C<sub>1-6</sub>alkylheterocyclic  
11 ring system having in the ring system 5 to 10 atoms with 1 to 4 of such atoms being  
12 selected from the group consisting of N, O and S; where R<sup>6</sup> taken with either of R<sup>7</sup> and  
13 R<sup>8</sup>, and/or R<sup>7</sup> taken with R<sup>8</sup>, can each form a 5 to 6 membered heterocyclic ring  
14 **[containing]** having from 1 to 4 atoms selected from the group consisting of N, O and S;

15 m is an integer from 0-3;

16 Z is a member selected from the group consisting of a direct link, C<sub>1-8</sub>alkyl,  
17 C<sub>3-8</sub>cycloalkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>carbocyclic aryl, or a five to ten membered  
18 heterocyclic ring system **[containing]** having 1-4 heteroatoms selected from the group  
19 consisting of N, O and S;

20 n is an integer from 0-3;

21 D is a member selected from the group consisting of a direct link, -CH<sub>2</sub>-, -O-,  
22 -N(R<sup>2</sup>)-, -C(=O)-, -S-, -SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>2</sup>)-, -N(R<sup>2</sup>)-SO<sub>2</sub>-, -OC(=O)-, -C(=O)O-,  
23 -C(=O)-N(R<sup>2</sup>)- and -N(R<sup>2</sup>)-C(=O)-;

24 R<sup>1</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>  
25 alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH,  
26 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, **[C<sub>0-8</sub>alkyl-OH,]** C<sub>1-C6</sub>alkyl-OH, C<sub>0-8</sub>alkyl-SH,  
27 -C(=O)NR<sup>2</sup>R<sup>3</sup>, -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or  
28 di-substituted amino group, wherein the substituted amino groups are independently  
29 substituted by at least one member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>  
30 alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, -SO<sub>2</sub>R<sup>2</sup>, C<sub>0-8</sub>alkyl-C(=O)OH and  
31 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, where R<sup>2</sup> and R<sup>3</sup> is as described above;

32 q is an integer from 0-3;

33 **[X is N or -CR<sup>12</sup>];**

34 R<sup>11</sup> and R<sup>12</sup> are independently a member selected from the group consisting of H,  
35 C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, C<sub>1-6</sub>alkylaryl,

36 C<sub>1-6</sub>alkyl-C<sub>3-8</sub>cycloalkyl, -O-R<sup>2</sup>, -O-C(=O)R<sup>2</sup>, -C<sub>1-8</sub>alkyl-O-R<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)R<sup>10</sup>,  
37 -C<sub>1-8</sub>alkyl-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>,  
38 -C<sub>1-8</sub>alkyl-NR<sup>10</sup>R<sup>10</sup>, -C<sub>1-8</sub>alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where R<sup>2</sup> is as described above and  
39 R<sup>10</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-</sub>  
40 <sub>8</sub>alkynyl, and wherein when two R<sup>10</sup> groups are present they may be taken together to  
41 form a saturated or unsaturated ring with the atom to which they are both attached;


42 p is an integer from 0-3;

43 E is a member selected from the group consisting of a direct link, -O-, -N(-R<sup>11</sup>)- ,  
44 where R<sup>11</sup> is as set forth above, phenylene, a bivalent 5 to 12 member heteroaryl group  
45 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S,  
46 and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
47 having 1-4 heteroatoms selected from the group consisting of N, O and S, wherein said  
48 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
49 substituted by from 0 to 5 R<sup>14</sup> groups;

50 J is a member selected from the group consisting of a direct link, a bivalent  
51 C<sub>3-8</sub>cycloalkyl group, phenylene, a 5 to 12 member bivalent heteroaryl group  
52 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S,  
53 and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
54 having 1-4 heteroatoms selected from the group consisting of N, O and S wherein said  
55 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
56 substituted by from 0 to 5 R<sup>14</sup> groups;

57 each R<sup>14</sup> group is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-</sub>  
58 <sub>8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH,  
59 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, [C<sub>0-8</sub>alkyl-OH,] C<sub>1-C6</sub>alkyl-OH, C<sub>0-8</sub>alkyl-SH,  
60 -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or di-substituted amino  
61 group, wherein the substituted amino groups are independently substituted by at least one  
62 member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl,  
63 C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH and C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl;

64 G is a member selected from the group consisting of: H; -CN; -OR<sup>17</sup>;



65 wherein


66 t is an integer from 0 to 6,

67 u is the integer 0 or 1, and R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> are  
 68 independently selected from the group consisting of H, -OH, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>  
 69 alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, a five to ten membered heterocyclic ring  
 70 system **[containing]** having 1-4 heteroatoms selected from the group consisting of N, O  
 71 and S; and C<sub>1-6</sub>alkylheterocyclic ring system having in the ring system 5 to 10 atoms with  
 72 1 to 4 of such atoms being selected from the group consisting of N, O and S; where [r<sup>18</sup>]  
 73 R<sup>18</sup> taken with R<sup>19</sup>, R<sup>22</sup> taken with either of R<sup>24</sup> and R<sup>25</sup>, and R<sup>24</sup> taken with R<sup>25</sup>, can each  
 74 independently form a 5 to 6 membered heterocyclic ring **[containing]** having from 1 to 4  
 75 atoms selected from the group consisting of N, O and S;


76 with the proviso that when G is H, -CN, -OR<sup>17</sup>, either E or J must contain at least  
 77 one N atom;

78 [and all pharmaceutically acceptable isomers, salts, hydrates, solvates and  
 79 **prodrug derivatives thereof**] or a pharmaceutically acceptable diastereomer, salt,  
 80 hydrate, and solvate thereof.

1 2. (Amended) A compound of formula II:



2  
 3 A is a member selected from the group consisting of:  $[R^2, -NR^3R^4,$   
 4  $-C(=O)NR^3R^4,]$



5  
 6 where  $[R^2, R^3, R^4,]$   $R^5, R^6, R^7, R^8,$  and  $R^9$  are independently selected from the group  
 7 consisting of H, -OH,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic  
 8 aryl, a five to ten membered heterocyclic ring system **[containing]** having 1-4  
 9 heteroatoms selected from the group consisting of N, O and S; and  $C_{1-6}$ alkylheterocyclic  
 10 ring system having in the ring system 5 to 10 atoms with 1 to 4 of such atoms being  
 11 selected from the group consisting of N, O and S; where  $[r^6]$   $R^6$  taken with either of  $R^7$   
 12 and  $R^8$ , and/or  $R^7$  taken with  $R^8$ , can each form a 5 to 6 membered heterocyclic ring  
 13 **[containing]** having from 1 to 4 atoms selected from the group consisting of N, O and S;

14 Z is a member selected from the group consisting of **[a direct link,]**  $C_{1-8}$ alkyl,

15 C<sub>3-8</sub>cycloalkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>carbocyclic aryl, or a five to ten membered  
16 heterocyclic ring system **[containing]** having 1-4 heteroatoms selected from the group  
17 consisting of N, O and S;

18 D is a member selected from the group consisting of a direct link, -CH<sub>2</sub>-, -O-,  
19 -N(R<sup>2</sup>)-, -C(=O)-, -S-, -SO<sub>2</sub>-, -SO<sub>2</sub>-N(R<sup>2</sup>)-, -N(R<sup>2</sup>)-SO<sub>2</sub>-, -OC(=O)-, -C(=O)O-,  
20 -C(=O)-N(R<sup>2</sup>)- and -N(R<sup>2</sup>)-C(=O)- provided that when Z is C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl,  
21 C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>carbocyclic aryl, then D is -O-, or -N(R<sup>2</sup>)-;

22 R<sup>1</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-</sub>  
23 <sub>8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH,  
24 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, [C<sub>0-8</sub>alkyl-OH,] C<sub>1-6</sub>alkyl-OH, C<sub>0-8</sub>alkyl-SH,  
25 -C(=O)NR<sup>2</sup>R<sup>3</sup>, -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or  
26 di-substituted amino group, wherein the substituted amino groups are independently  
27 substituted by at least one member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-</sub>  
28 <sub>8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, -SO<sub>2</sub>R<sup>2</sup>, C<sub>0-8</sub>alkyl-C(=O)OH and  
29 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, **[where R<sup>2</sup> and R<sup>3</sup> is as described above];**

30 R<sup>2</sup>, R<sup>3</sup> are independently selected from the group consisting of H, -OH, C<sub>1-8</sub>alkyl,  
31 C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, a five to ten membered  
32 heterocyclic ring system having 1-4 heteroatoms selected from the group consisting of N,  
33 O and S; and C<sub>1-6</sub>alkylheterocyclic ring system having in the ring system 5 to 10 atoms  
34 with 1 to 4 of such atoms being selected from the group consisting of N, O and S;

35 q is an integer from 0-3;

36 R<sup>11</sup> is independently a member selected from the group consisting of H, C<sub>1-8</sub>alkyl,  
37 C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, C<sub>1-6</sub>alkylaryl,  
38 C<sub>1-6</sub>alkyl-C<sub>3-8</sub>cycloalkyl, -O-R<sup>2</sup>, -O-C(=O)R<sup>2</sup>, -C<sub>1-8</sub>alkyl-O-R<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)R<sup>10</sup>,  
39 -C<sub>1-8</sub>alkyl-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>,  
40 -C<sub>1-8</sub>alkyl-NR<sup>10</sup>R<sup>10</sup>, -C<sub>1-8</sub>alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where R<sup>2</sup> is as described above and


41  $R^{10}$  is a member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl, and wherein when two  $R^{10}$  groups are present they may be taken together to  
42 form a saturated or unsaturated ring with the atom to which they are both attached;  
43  
44 p is an integer from 0-2;

45 E is a member selected from the group consisting of a direct link, -O-, -N( $R^{11}$ )-, where  $R^{11}$  is as set forth above, phenylene, a bivalent 5 to 12 member heteroaryl group  
46 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S, and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
47 having 1-4 heteroatoms selected from the group consisting of N, O and S, wherein said  
48 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
49 substituted by from 0 to 5  $R^{14}$  groups;

52 J is a member selected from the group consisting of a direct link, a bivalent  
53  $C_{3-8}$ cycloalkyl group, phenylene, a 5 to 12 member bivalent heteroaryl group  
54 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S, and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
55 having 1-4 heteroatoms selected from the group consisting of N, O and S wherein said  
56 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
57 substituted by from 0 to 5  $R^{14}$  groups;

59 each  $R^{14}$  group is a member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl, halogen, polyhaloalkyl,  $C_{0-8}$ alkyl-C(=O)OH,  
60  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl, -CN, -NO<sub>2</sub>, [ **$C_{0-8}$ alkyl-OH,**]  $C_{1-6}$ alkyl-OH,  $C_{0-8}$ alkyl-SH,  
61 -O- $R^2$  and -O-C(=O) $R^2$ , an unsubstituted amino group, a mono- or di-substituted amino  
62 group, wherein the substituted amino groups are independently substituted by at least one  
63 member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  
64  $C_{3-8}$ cycloalkyl, polyhaloalkyl,  $C_{0-8}$ alkyl-C(=O)OH and  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl;

66 G is a member selected from the group consisting of: H; -CN; -OR<sup>17</sup>;



67 wherein


68 t is an integer from 0 to 6,

69 u is the integer 0 or 1, and R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> are  
 70 independently selected from the group consisting of H, -OH, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>  
 71 alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, a five to ten membered heterocyclic ring  
 72 system [**containing**] having 1-4 heteroatoms selected from the group consisting of N, O  
 73 and S; and C<sub>1-6</sub>alkylheterocyclic ring system having in the ring system 5 to 10 atoms with  
 74 1 to 4 of such atoms being selected from the group consisting of N, O and S; where [R<sup>18</sup>]  
 75 R<sup>18</sup> taken with R<sup>19</sup>, R<sup>22</sup> taken with either of R<sup>24</sup> and R<sup>25</sup>, and R<sup>24</sup> taken with R<sup>25</sup>, can each  
 76 independently form a 5 to 6 membered heterocyclic ring [**containing**] having from 1 to 4  
 77 atoms selected from the group consisting of N, O and S;

78 with the proviso that when G is H, -CN, -OR<sup>17</sup>, either E or J must contain at least  
 79 one N atom;

80 [and all pharmaceutically acceptable isomers, salts, hydrates, solvates and  
81 prodrug derivatives thereof] or a pharmaceutically acceptable diastereomer, salt,  
82 hydrate, and solvate thereof.

1 5. (Amended) A compound of formula III:



2  
3  
4

5 wherein:

6  $R^8$  is selected from the group consisting of H, -OH,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-}$   
7  $8$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic aryl, a five to ten membered heterocyclic ring  
8 system [containing] having 1-4 heteroatoms selected from the group consisting of N, O  
9 and S; and  $C_{1-6}$ alkylheterocyclic ring system having in the ring system 5 to 10 atoms with  
10 1 to 4 of such atoms being selected from the group consisting of N, O and S;

11  $R^1$  is a member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-}$   
12  $8$ alkynyl,  $C_{3-8}$ cycloalkyl, halogen, polyhaloalkyl,  $C_{0-8}$ alkyl-C(=O)OH,  
13  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl, -CN, -NO<sub>2</sub>, [ $C_{0-8}$ alkyl-OH],  $C_{1-6}$ alkyl-OH,  $C_{0-8}$ alkyl-SH,  
14 -C(=O)NR<sup>2</sup>R<sup>3</sup>, -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or  
15 di-substituted amino group, wherein the substituted amino groups are independently  
16 substituted by at least one member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-}$   
17  $8$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl, polyhaloalkyl, -SO<sub>2</sub>R<sup>2</sup>,  $C_{0-8}$ alkyl-C(=O)OH and  
18  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl, where R<sup>2</sup> and R<sup>3</sup> is as described above;

19  $R^2$  is selected from the group consisting of H, -OH,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-}$   
20  $8$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic aryl, a five to ten membered heterocyclic ring



21 system **[containing]** having 1-4 heteroatoms selected from the group consisting of N, O  
22 and S; and C<sub>1-6</sub>alkylheterocyclic ring system having in the ring system 5 to 10 atoms with  
23 1 to 4 of such atoms being selected from the group consisting of N, O and S;  
24 q is 0-3;


25 R<sup>11</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl,  
26 C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, C<sub>1-6</sub>alkylaryl, C<sub>1-6</sub>alkyl-C<sub>3-8</sub>cycloalkyl,  
27 -O-R<sup>2</sup>, -O-C(=O)R<sup>2</sup>, -C<sub>1-8</sub>alkyl-O-R<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)R<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)OR<sup>10</sup>,  
28 -C<sub>1-8</sub>alkyl-O-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>, -C<sub>1-8</sub>alkyl-NR<sup>10</sup>R<sup>10</sup>,  
29 -C<sub>1-8</sub>alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where R<sup>2</sup> is as described above and R<sup>10</sup> is a member  
30 selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, and wherein  
31 when two R<sup>10</sup> groups are present they may be taken together to form a saturated or  
32 unsaturated ring with the atom to which they are both attached;  
33 p is an integer from 0-2;

34 E is a member selected from the group consisting of a direct link, -O-, -N(-R<sup>11</sup>)- ,  
35 where R<sup>11</sup> is as set forth above, phenylene, a bivalent 5 to 12 member heteroaryl group  
36 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S,  
37 and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
38 having 1-4 heteroatoms selected from the group consisting of N, O and S, wherein said  
39 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
40 substituted by from 0 to 5 R<sup>14</sup> groups;

41 J is a member selected from the group consisting of a direct link, a bivalent  
42 C<sub>3-8</sub>cycloalkyl group, phenylene, a 5 to 12 member bivalent heteroaryl group  
43 **[containing]** having 1 to 4 heteroatoms selected from the group consisting of N, O and S,  
44 and a five to ten membered non-aromatic bivalent heterocyclic ring system **[containing]**  
45 having 1-4 heteroatoms selected from the group consisting of N, O and S wherein said  
46 heteroaryl and said non-aromatic heterocyclic ring structure may be independently  
47 substituted by from 0 to 5 R<sup>14</sup> groups;

each  $R^{14}$  group is a member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl, halogen, polyhaloalkyl,  $C_{0-8}$ alkyl-C(=O)OH,  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl, -CN, -NO<sub>2</sub>, [ **$C_{0-8}$ alkyl-OH,**]  $C_{1-6}$ alkyl-OH,  $C_{0-8}$ alkyl-SH, -O- $R^2$  and -O-C(=O) $R^2$ , an unsubstituted amino group, a mono- or di-substituted amino group, wherein the substituted amino groups are independently substituted by at least one member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl, polyhaloalkyl,  $C_{0-8}$ alkyl-C(=O)OH and  $C_{0-8}$ alkyl-C(=O)O- $C_{1-8}$ alkyl;

G is a member selected from the group consisting of: H; -CN; -OR<sup>17</sup>;



wherein

t is an integer from 0 to 6,


u is the integer 0 or 1, and  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$  and  $R^{26}$  are independently selected from the group consisting of H, -OH,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic aryl, a five to ten membered heterocyclic ring system **[containing]** having 1-4 heteroatoms selected from the group consisting of N, O and S; and  $C_{1-6}$ alkylheterocyclic ring system having in the ring system 5 to 10 atoms with 1 to 4 of such atoms being selected from the group consisting of N, O and S; where [ $r^{18}$ ]

64  $R^{18}$  taken with  $R^{19}$ ,  $R^{22}$  taken with either of  $R^{24}$  and  $R^{25}$ , and  $R^{24}$  taken with  $R^{25}$ , can each  
 65 independently form a 5 to 6 membered heterocyclic ring [containing] having from 1 to 4  
 66 atoms selected from the group consisting of N, O and S;

67 with the proviso that when G is H, -CN, -OR<sup>17</sup>, either E or J must contain at least  
 68 one N atom;

69 [and all pharmaceutically acceptable isomers, salts, hydrates, solvates and  
 70 prodrug derivatives thereof] or a pharmaceutically acceptable diastereomer, salt,  
 71 hydrate, and solvate thereof.


1 9. A compound of formula IV:



2

3 wherein:

4 A is a member selected from the group consisting of:  $R^2$ ,  $-NR^3R^4$ ,  $-C(=O)NR^3R^4$ ,



5

6 where  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ , and  $R^9$  are independently selected from the group

7 consisting of H, -OH, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic

8 aryl, a five to ten membered heterocyclic ring system **[containing]** having 1-4  
9 heteroatoms selected from the group consisting of N, O and S; and C<sub>1-6</sub>alkylheterocyclic  
10 ring system having in the ring system 5 to 10 atoms with 1 to 4 of such atoms being  
11 selected from the group consisting of N, O and S; where [**r**<sup>6</sup>] **R**<sup>6</sup> taken with either of R<sup>7</sup>  
12 and R<sup>8</sup>, and/or R<sup>7</sup> taken with R<sup>8</sup>, can each form a 5 to 6 membered heterocyclic ring  
13 **[containing]** having from 1 to 4 atoms selected from the group consisting of N, O and S;


14 Z is a member selected from the group consisting of a direct link, C<sub>1-8</sub>alkyl,  
15 C<sub>3-8</sub>cycloalkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>carbocyclic aryl, or a five to ten membered  
16 heterocyclic ring system **[containing]** having 1-4 heteroatoms selected from the group  
17 consisting of N, O and S;  
18 n is 0-3;

19 D is a member selected from the group consisting of: -CH<sub>2</sub>-, -O-, -N R<sup>2</sup>, -C(=O)-,  
20 -S-, -SO<sub>2</sub>-, -SO<sub>2</sub>-NR<sup>2</sup>, -NR<sup>2</sup>-SO<sub>2</sub>-, -OC(=O)-, -C(=O)NR<sup>2</sup>, and -NR<sup>2</sup>-C(=O)-;

21 R<sup>1</sup> and R<sup>14</sup> are independently a member selected from the group consisting of H,  
22 C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl,  
23 C<sub>0-8</sub>alkyl-C(=O)OH, C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, [**C**<sub>0-8</sub>**alkyl-OH**], C<sub>1-</sub>  
24 C<sub>6</sub>**alkyl-OH**, C<sub>0-8</sub>alkyl-SH, -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a  
25 mono- or di-substituted amino group, wherein the substituted amino groups are  
26 independently substituted by at least one member selected from the group consisting of  
27 H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH  
28 and C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl;  
29 q is 0-3;

30 R<sup>11</sup> is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl,  
31 C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, C<sub>1-6</sub>alkylaryl, C<sub>1-6</sub>alkyl-C<sub>3-8</sub>cycloalkyl,  
32 -O-R<sup>2</sup>, -O-C(=O)R<sup>2</sup>, -C<sub>1-8</sub>alkyl-O-R<sup>10</sup>, -C<sub>1-8</sub>alkyl-O-C(=O)R<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)OR<sup>10</sup>,  
33 -C<sub>1-8</sub>alkyl-O-C(=O)OR<sup>10</sup>, -C<sub>1-8</sub>alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>, -C<sub>1-8</sub>alkyl-NR<sup>10</sup>R<sup>10</sup>,  
34 -C<sub>1-8</sub>alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where R<sup>2</sup> is as described above and R<sup>10</sup> is a member


- 35 selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, and wherein  
 36 when two R<sup>10</sup> groups are present they may be taken together to form a saturated or  
 37 unsaturated ring with the atom to which they are both attached;  
 38 G is a member selected from the group consisting of: H; -CN; -OR<sup>17</sup>;



- 39 wherein  
 40 t is an integer from 0 to 6,  
 41 u is the integer 0 or 1, and R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> are  
 42 independently selected from the group consisting of H, -OH, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>  
 43 alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>6-12</sub>carbocyclic aryl, a five to ten membered heterocyclic ring  
 44 system **[containing]** having 1-4 heteroatoms selected from the group consisting of N, O  
 45 and S; and C<sub>1-6</sub>alkylheterocyclic ring system having in the ring system 5 to 10 atoms with  
 46 1 to 4 of such atoms being selected from the group consisting of N, O and S; where [r<sup>18</sup>]  
 47 R<sup>18</sup> taken with R<sup>19</sup>, R<sup>22</sup> taken with either of R<sup>24</sup> and R<sup>25</sup>, and R<sup>24</sup> taken with R<sup>25</sup>, can each  
 48 independently form a 5 to 6 membered heterocyclic ring **[containing]** having from 1 to 4  
 49 atoms selected from the group consisting of N, O and S;  
 50 with the proviso that when G is H, -CN, -OR<sup>17</sup>, either E or J must contain at least

51 one N atom;  
52 [and all pharmaceutically acceptable isomers, salts, hydrates, solvates and  
53 prodrug derivatives thereof] or a pharmaceutically acceptable diastereomer, salt,  
54 hydrate, and solvate thereof.

1 11. A compound of formula V:



2  
3  
4 wherein:

5  $R^2$ ,  $R^6$ , and  $R^9$  are independently selected from the group consisting of H, -OH,  
6  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic aryl, a five to ten  
7 membered heterocyclic ring system [containing] having 1-4 heteroatoms selected from  
8 the group consisting of N, O and S; and  $C_{1-6}$ alkylheterocyclic ring system having in the  
9 ring system 5 to 10 atoms with 1 to 4 of such atoms being selected from the group  
10 consisting of N, O and S;

11  
12  $R^{11}$  is independently a member selected from the group consisting of H,  
13  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{6-12}$ carbocyclic aryl,  $C_{1-6}$ alkylaryl,  
14  $C_{1-6}$ alkyl- $C_{3-8}$ cycloalkyl, -O- $R^2$ , -O-C(=O) $R^2$ , - $C_{1-8}$ alkyl-O- $R^{10}$ , - $C_{1-8}$ alkyl-O-C(=O) $R^{10}$ ,  
15 - $C_{1-8}$ alkyl-C(=O)OR<sup>10</sup>, - $C_{1-8}$ alkyl-O-C(=O)OR<sup>10</sup>, - $C_{1-8}$ alkyl-C(=O)NR<sup>10</sup>R<sup>10</sup>,  
16 - $C_{1-8}$ alkyl-NR<sup>10</sup>R<sup>10</sup>, - $C_{1-8}$ alkyl-NR<sup>10</sup>C(=O)R<sup>10</sup>, -SR<sup>10</sup>, where  $R^2$  is as described above and  
17  $R^{10}$  is a member selected from the group consisting of H,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-}$   
18  $C_{2-8}$ alkynyl, and wherein when two  $R^{10}$  groups are present they may be taken together to

19 form a saturated or unsaturated ring with the atom to which they are both attached;  
20  
21 each R<sup>14</sup> group is a member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-</sub>  
22 <sub>8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>3-8</sub>cycloalkyl, halogen, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH,  
23 C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl, -CN, -NO<sub>2</sub>, [**C<sub>0-8</sub>alkyl-OH,**] C<sub>1-C<sub>6</sub></sub>alkyl-OH, C<sub>0-8</sub>alkyl-SH,  
24 -O-R<sup>2</sup> and -O-C(=O)R<sup>2</sup>, an unsubstituted amino group, a mono- or di-substituted amino  
25 group, wherein the substituted amino groups are independently substituted by at least one  
26 member selected from the group consisting of H, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl,  
27 C<sub>3-8</sub>cycloalkyl, polyhaloalkyl, C<sub>0-8</sub>alkyl-C(=O)OH and C<sub>0-8</sub>alkyl-C(=O)O-C<sub>1-8</sub>alkyl;  
28 **[and all pharmaceutically acceptable isomers, salts, hydrates, solvates and**  
29 **prodrug derivatives thereof]** or a pharmaceutically acceptable diastereomer, salt,  
30 hydrate, and solvate thereof.